Cross-border Victory: Russian Patient Achieves Complete Remission with BCMA CAR-T Therapy at Ludaobei Hospital

At Ludaobei Hospital’s Lymphoma & Myeloma Center, we witnessed yet another remarkable success in the fight against relapsed/refractory lymphoma. A 58-year-old male patient from Russia, Mr. Safov, has returned home with the news of complete remission (CR) after undergoing an innovative dual-target CAR-T therapy at our hospital. This marks another triumph in treating difficult-to-treat, relapsed lymphomas through multidisciplinary collaboration and cutting-edge technology.

Mr. Safov was diagnosed with advanced stage Diffuse Large B-Cell Lymphoma (DLBCL) in April 2024 and underwent initial treatment, including R-CHOP chemotherapy and radiotherapy. After showing early signs of remission, his disease relapsed in early 2025, with a high tumor burden and central nervous system (CNS) involvement. Faced with limited options in Russia, Safov traveled to China for treatment.

At Ludaobei Hospital, the medical team quickly formulated a treatment plan that included high-dose chemotherapy and a dual-target BCMA CAR-T cell therapy, aiming to penetrate the blood-brain barrier and tackle both peripheral and CNS lymphoma. After two cycles of treatment, Safov achieved a remarkable complete remission (CR), with no sign of malignant cells and a significant reduction in tumor activity.

The successful treatment not only saved Mr. Safov’s life but also highlighted the potential of CAR-T therapy in managing complex, relapsed lymphoma cases, including those with CNS involvement. The patient was able to return home, full of gratitude, with the support of a customized follow-up plan to ensure his continued recovery.

Key Takeaways:

• Dual-target BCMA CAR-T therapy has shown high efficacy for relapsed/refractory lymphoma, including cases with CNS involvement.

• Mr. Safov's case exemplifies the success of personalized, cutting-edge treatments at Ludaobei Hospital.

• Multidisciplinary collaboration and international patient care remain core to the hospital’s approach in treating complex blood cancers.